Clinical trials: Tissue Plasminogen Activator
Stroke
CLOTBUST Hands-Free: A Phase I/II Pilot Safety Trial
The purpose of CLOTBUST-HF is to determine the safety of a novel, external Hands-Free transcranial Doppler (TCD) ultrasound system in healthy volunteers and ischemic stroke patients.
- Trial name
- CLOTBUST-HF (NCT01240356)
- Testing
- 2-MHz transcranial Doppler ultrasound, 2-MHz transcranial Doppler ultrasound insonation
- Where
- 2 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Catheter Occlusion, Thrombosis
Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality
To evaluate the efficacy and safety of CUSA-081 (diluted reteplase) in the restoration of central venous access device (CVAD) functionality in participants 18 years and older.
- Trial name
- READY1 (NCT03594175)
- Testing
- CUSA-081, Alteplase
- Where
- 77 sites in United States, Argentina and 5 more
- Volunteers
- 462 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Stroke, Ischemic Stroke
Feasibility Study of IV Recombinant Tissue Plasminogen Activator (rtPA) vs. Primary Endovascular Therapy for Acute Ischemic Stroke
This pilot trial will be the first step toward direct comparison of delivery of endovascular reperfusion therapy to intravenous recombinant tissue plasminogen activator (rt-PA) in a time-to-treatment framework shown as most…
- Trial name
- EARLY (NCT01869478)
- Testing
- Intravenous Thrombolysis, Endovascular Arterial Reperfusion
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Ischemic Stroke
Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke
Randomized controlled clinical trial to estimate overall treatment benefit (improvement in disability) among stroke patients treated with rt-PA who are randomized to also receive either low-dose Argatroban, high-dose Argatroban…
- Trial name
- ARTSS-2 (NCT01464788)
- Testing
- Low Dose Argatroban, High Dose Argatroban, rt-PA (alteplase)
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Andrew D. Barreto, MD
Intracerebral Hemorrhage
Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III
A phase III, randomized, case-controlled, open-label, 500-subject clinical trial of minimally invasive surgery plus rt-PA in the treatment of intracerebral hemorrhage (ICH).
- Trial name
- MISTIE-III (NCT01827046)
- Testing
- rt-PA
- Where
- 84 sites in United States, Australia and 7 more
- Volunteers
- 499 people
- Sponsor
- Johns Hopkins University
Cerebral Infarction, Brain Ischemia
Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke
Based on previous studies comparing Duteplase[a recombinant tissue plasminogen activator (rt-PA) very similar to alteplase] doses, we performed a clinical trial with 0.6mg/kg, which is lower than the internationally approved…
- Trial name
- NCT00147316
- Testing
- Alteplase
- Where
- Japan
- Volunteers
- 103 people
- Sponsor
- Tanabe Pharma Corporation
Stroke
Interventional Management of Stroke (IMS) III Trial
The purpose of this study is to compare two different treatment approaches to recanalization started within 3 hours of symptom onset-combined intravenous (IV) and endovascular therapy and standard intravenous (IV) rt-PA alone.
- Trial name
- IMSIII (NCT00359424)
- Testing
- IV rt-PA alone, endovascular therapy
- Where
- 71 sites in United States, Australia and 6 more
- Volunteers
- 656 people
- Sponsor
- Joseph Broderick
Plastic Bronchitis, Protein-Losing Enteropathies
Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis
Plastic bronchitis (PB) is a rare, most often pediatric disease characterized by the formation of obstructive airway casts primarily composed of fibrin.
- Conditions
- Plastic Bronchitis, Protein-Losing Enteropathies, Healthy
- Trial name
- PLATyPuS (NCT02315898)
- Testing
- Treatment-inhaled tPA
- Where
- 6 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Pulmonary Embolism, Acute Pulmonary Embolism
Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy
The purpose of this study is to determine if the EKOS EkoSonic® Endovascular Device when used in conjunction with recombinant tissue plasminogen activator (t-PA) as a treatment for acute PE will decrease the ratio of right…
- Conditions
- Pulmonary Embolism, Acute Pulmonary Embolism, Sub-massive Pulmonary Embolism, Massive Pulmonary Embolism
- Trial name
- SEATTLE II (NCT01513759)
- Testing
- recombinant tissue plasminogen activator, EKOS EkoSonic Endovascular System
- Where
- 22 sites in United States
- Volunteers
- 150 people
- Sponsor
- Boston Scientific Corporation
Pulmonary Embolism
tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden
To demonstrate the efficacy and safety of the Bashir™ Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using low dose r-tPA for the treatment of acute submassive pulmonary embolism.
- Trial name
- RESCUE (NCT04248868)
- Testing
- The Bashir™ Endovascular Catheter, r-tPA
- Where
- 19 sites in United States
- Volunteers
- 109 people
- Sponsor
- Thrombolex, Inc.